Navigation Links
Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
Date:11/7/2013

d net loss per share excludes the effect of the same items from net loss per share. Management believes those costs do not reflect the ongoing performance of the core business. Management uses adjusted net income or loss to prepare operating budgets and forecasts and to measure our performance against those budgets and forecasts. Reconciliations of net loss, the GAAP measure most directly comparable to adjusted net loss, and net loss per share, the GAAP measure most directly comparable to adjusted net loss per share, are provided on the attached schedule.

Conference Call InformationA conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place today, November 7, at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website.  

To access the live teleconference call, dial 877-883-0383 in the U.S. and Canada, and 412-902-6506 for other international callers. Please use code 1655358. If you are unable to listen to the live webcast, a teleconference replay will be available through Friday, November 29, 2013. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10035907.

The conference call webcast is accessible through the "Investors" section of the Sequenom Web site at www.sequenom.com/invest. An online replay will be available following the initial broadcast until Friday, November 29, 2013. 

About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. The company was founded in 1994 and
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Sequenom, Inc. Announces Date Of Third Quarter 2013 Financial Results And Conference Call
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
8. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
10. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
11. NxStage Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and CTO, ... scientific poster describing an innovative diagnostic procedure for the ... New Light on Disease (SPEC) conference in Krakow, ... poster entitled, "Development of in vitro Diagnostics for Detection ... discussed during the conference poster session on Tuesday, August ...
(Date:8/19/2014)... Aug. 19, 2014  As power morcellator lawsuits ... Bernstein Liebhard LLP notes that women in need ... a number of options that do not involve ... According to a report published by The Wall ... options include a mini-laparotomy and vaginal hysterectomy. Non-surgical ...
(Date:8/19/2014)... -- Research and Markets has announced the addition ... Business Report" report to their offering. ... Drugs in US$ Million by the following Brands: Humatrope, Norditropin, ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , and Rest of World. ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Global Human Growth Hormone Drugs - Strategic Business Report 2014 2
... Dec. 16 Vivakor, Inc. (OTC Bulletin Board: VIVK) ... out of Walnut Creek, California and its affiliate group, ... Consulting has been retained by Vivakor to assist with ... recently reported acquisition strategy. Specifically, Baker Consulting is exploring ...
... , EVANSTON, Ill., Dec. ... innovative treatments for depression and other CNS disorders based on ... presented at a major medical meeting showed that its lead ... signs of the CNS-related side effects seen with other drugs ...
Cached Medicine Technology:Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6
(Date:8/20/2014)... have found a novel approach to treating cancer - ... edition of Science Translational Medicine shows that ... sent by nerves that are linked to cancer stem ... of Botox made the treatment cheap, safe and efficient. ... mice, and will soon start testing on humans. , ...
(Date:8/20/2014)... 2014 Quincy Bioscience, a Wisconsin-based biotech ... of the fastest growing private companies in the ... No. 2,941, Quincy Bioscience is honored again to be ... States. , Quincy Bioscience is manufacturer of Prevagen brand ... protein originally discovered in jellyfish and clinically shown to ...
(Date:8/20/2014)... DALLAS (PRWEB) August 20, 2014 Caddis ... track records of any healthcare real estate company in ... of medical assets valued at $500 million, including more ... of that significant growth, including expansions into new geographic ... expanded capabilities, company executives are pleased to announce an ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Braverman Eye ... the help of their experienced surgeons trained in PresbyLasik. ... to regain their lost or inaccurate vision. Their diligent ... Lasik surgery is making it possible for Presbyopia patients ... which occurs normally in people in the age group ...
(Date:8/20/2014)... August 20, 2014 Texas Medical Research Associates ... The study will help test the effectiveness of a new ... high cholesterol may be eligible to participate in the study. ... in the blood can lead to cardiovascular disease, the no. ... can help reduce the risk of heart disease and stroke. ...
Breaking Medicine News(10 mins):Health News:Treating gastric cancer -- with Botox 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2Health News:Texas Medical Research Associates Announce New Study 2
... Jenifer Goodwin HealthDay Reporter , TUESDAY, June ... U.S. Preventive Services Task Force recommendations that women in ... and furious. Using email, social networking sites and electronic ... , Researchers say the magnitude of the reaction heralded ...
... have discovered a potent and highly-debilitating toxin in the ... is now prompting investigations of other marine mammals in ... by marine algae common on coral reefs, and accumulates ... the human disease caused by ciguatoxin, affects thousands of ...
... of Technology & Innovation, Proceedings of the National ... future and enormous need for stem cell therapeutics that ... deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... replacement" procedures to restructure damaged organs, tissues and cells, ...
... IN THE ICU , Intensive care units are ... the future. A recent study, conducted by physicians from ... in New York, NY, studying 590 daytime admissions in ... can help address these staff shortages. In the ...
... consume an average of 13 hours of media content a ... according to a Northwestern University report, the first national study ... ethnicity. "In the past decade, the gap between minority ... and quadrupled for Hispanics," says Northwestern Professor Ellen Wartella, who ...
... Cincinnati (UC) Department of Emergency Medicine has received a ... to study the implementation of electronic health records in ... support the work of Michael Ward, MD, an assistant ... the past year focusing on simulation modeling in operations ...
Cached Medicine News:Health News:Is Social Networking Changing the Face of Medicine? 2Health News:Is Social Networking Changing the Face of Medicine? 3Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: